Which of the following statements if true most seriously weakens the argument of Medicines sans Frontiers against the data-exclusivity agreement of the TPP on Biologics? Options: A . &nbspManufacturers in developing nations will use shared data on Biologics to develop drugs for the export market. B . &nbspGovernments in developing countries may impose tough regulations on drug testing of Biologics. C . &nbspBiologics may face stiff competition from a new class of generic drugs designed to combat widespread diseases like malaria. D . &nbspManufacturers of Biologics in developing nations may offer only 10% price reduction on these drugs as compared to the original versions. E . &nbspBoth B and C

Answer: Option D : D Medicines sans Frontiers argues that a 12 year data exclusivity term on Biologics will bestow an unfair advantage to American pharma majors as they will be able to sell them at high prices in developing markets also during this period. They contend that if the data on these drugs is shared with generic drug makers, low cost generic versions of these drugs developed by them will be much more affordable to the people living in poorer countries. So a statement that negates the availability of generics at a significantly low price will most seriously weaken the argument of Medicines sans Frontiers against a shorter data exclusivity term and option D does that.